Results Snapshot
Quarterly Analysis Highlights - YoY
Net Sales
YoY Growth in quarter ended Mar 2026 is 14.94% vs 6.21% in Mar 2025
Consolidate Net Profit
YoY Growth in quarter ended Mar 2026 is 63.97% vs -16.24% in Mar 2025
Operating Profit (PBDIT) excl Other Income
YoY Growth in quarter ended Mar 2026 is 55.19% vs -58.76% in Mar 2025
Interest
YoY Growth in quarter ended Mar 2026 is -100.00% vs 0.00% in Mar 2025
Operating Profit Margin (Excl OI)
YoY Growth in quarter ended Mar 2026 has improved from Mar 2025
Compare Quarterly Results Of Theravance Biopharma, Inc. With
Quarterly - Net Sales
QoQ Growth in quarter ended Mar 2026 is -61.44% vs 129.50% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 14.94% vs 6.21% in Mar 2025
Quarterly - Consolidate Net Profit
QoQ Growth in quarter ended Mar 2026 is -108.03% vs 1,594.44% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 63.97% vs -16.24% in Mar 2025
Quarterly - Operating Profit (PBDIT)
QoQ Growth in quarter ended Mar 2026 is -136.13% vs 482.00% in Dec 2025
YoY Growth in quarter ended Mar 2026 is 55.19% vs -58.76% in Mar 2025
Quarterly - Interest
Quarterly - Operating Profit Margin (Excl OI)
QoQ Growth in quarter ended Mar 2026 has fallen from Dec 2025
YoY Growth in quarter ended Mar 2026 has improved from Mar 2025






